Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: A population-based study

Metabolism: Clinical and Experimental

Volumn 47, Issue 10, 1998, Pages 1205-1210

  Pozzilli, Paolo ^a   Visalli, Natalia ^b   Buzzetti, Raffaella ^b   Cavallo, M Gisella ^b   Marietti, Giovanni ^b   Hawa, Mohammed ^b   Leslie, R David G ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A1C; INSULIN; PANCREAS ISLET CELL ANTIBODY; PHOSPHATASE;

ADULT; AGE; ANTIBODY DETECTION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031721173     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90324-9     Document Type: Article

References (38)

1. Atkinson M, Maclaren NK: The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 331:1428-1436, 1994
2. Pozzilli P, Maclaren NK: Immunotherapy at clinical diagnosis of insulin dependent diabetes: An approach still worth considering. Trends Endocrinol Metab 4:101-105, 1993
3. Skyler JS, Marks JB: Immune intervention in type 1 diabetes mellitus. Diabetes Rev 1:15-42, 1993
4. Shah SC, Malone JI, Simpson NE: A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 350:550-552, 1989
5. Andreani D, Di Mario U, Pozzilli P: Prediction, prevention and early intervention in insulin dependent diabetes. Diabetes Metab Rev 7:61-77, 1991
6. Klein R, Klein BEK, Moss SC: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. The relationship of C-peptide to the incidence and progression of diabetic retinopathy. Diabetes 44:796-801, 1995
7. Hamilton DV, Mundia SS, Lister J: Mode of presentation of juvenile diabetes. BMJ 2:211-212, 1976
8. Pinkney JH, Bingley PJ, Sawtell PA, et al: The Barts Oxford Study Group. Presentation and progress of childhood diabetes mellitus: A prospective population based study. Diabetologia 37:70-74, 1994
9. Drash AL: in Drash AL (ed): Clinical Care of the Diabetic Child. Chicago, IL, Year Book Medical, 1987, pp 35-47
10. Snorgaard O, Larsen LH, Binder C: Homogeneity in pattern of decline of beta-cell function in IDDM. Diabetes Care 15:1009-1015, 1992
11. Pozzilli P, Andreani D: Type I diabetes at presentation: The scene changes. Diabet Med 7:762-763, 1990
12. Green A, Gale EAM, Patterson CC: Incidence of childhood insulin dependent diabetes mellitus: The EURODIAB ACE Study. Lancet 339:905-909, 1992
13. Sebastiani L, Visalli N, Adorisio E, et al: A five year (1989-1993) prospective study of the incidence of insulin dependent diabetes in Rome and the Lazio region in the age group 0-14 years. Diabetes Care 19:70-73, 1996
14. Pozzilli P, Visalli N, Boccuni ML, et al: Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin dependent diabetes. Diabet Med 11:98-104, 1994
15. Pozzilli P, Visalli N, Signore A, et al: Double blind trial of nicotinamide in recent onset insulin dependent diabetes mellitus. Diabetologia 38:848-852, 1995
16. Pozzilli P on behalf of the IMDIAB Study Group: BCG vaccine in recent-onset IDDM. Lancet 349:1520-1521, 1997
17. Pozzilli P, Visalli N, Signore A, et al: Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin dependent diabetes (The IMDIAB IV Study). Eur J Endocrinol 137:234-239, 1997
18. Petersen JS, Hejnaes KR, Moody A, et al: Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay. Diabetes 43:459-467, 1994
19. Lan MS, Lu J, Goto Y, et al: Molecular cloning and identification of a receptor type protein tyrosine phosphatase, IA-2 from human insulinoma. DNA Cell Biol 13:505-514, 1994
20. Lu J, Notkins AL: Isolation, sequence and expression of a novel mouse brain cDNA, mIA-2, and its relatedness to members of the protein tyrosine phosphatase family. Biochem Biophys Res Commun 204:930-936, 1994
21. Payton MA, Hawkes CJ, Christie MR: Relationship of the 37,000 and 40,000 Mr tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 96:1506-1511, 1995
22. Schmidli RS, Colman PG, Bonifacio E, et al: Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies. The Second International GADAb Workshop. Diabetes 44:636-640, 1995
23. Bingley PJ, Bonifacio E, Gale EAM: Can we really predict IDDM? Diabetes 42:213-220, 1993
24. Lampasona V, Bearzatto M, Genovese S, et al: Autoantibodies in insulin-dependent diabetes recognise distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol 157:2707-2711, 1996
25. Bonifacio E, Genovese S, Braghi S, et al: Islet autoantibody markers in IDDM: Risk assessment strategies yielding high sensitivity. Diabetologia 38:816-822, 1995
26. Genovese S, Bonfanti R, Bazzigaluppi E, et al: Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM. Diabetologia 39:1223-1226, 1996
27. Verge CF, Gianani R, Kawasaki E, et al: Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD and ICA512bdc/IA-2 autoantibodies. Diabetes 45:926-933, 1996
28. Seissler J, Morgnthaler NG, Achenbach P, et al: Combined screening for autoantibodies to IA-2 and antibodies to glutamic acid decarboxylase in first-degree relatives of patients with IDDM. Diabetologia 39:1351-1356, 1996
29. Hawa MI, Rowe RE, Lan MS, et al: Antibodies to tyrosine phophatase-like molecule in type 1 diabetes: A new predictive marker of the disease. Diabetes 46:1270-1275, 1997
30. Bingley PJ, Bonifacio E, Williams AJK, et al: Prediction of IDDM in the general population: Strategies based on combinations of autoantibody markers. Diabetes 46:1701-1710, 1997
31. Bingley PJ, Bonifacio E, Shattock M, et al: Can islet cell antibodies predict IDDM in the general population? Diabetes Care 16:45-50, 1993
32. Amiel SA, Caprio S, Sherwin RS, et al: Insulin resistance of puberty: A defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 72:277-282, 1991
33. Madsbad S, Krarup T, Regeur L, et al: Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment. Acta Endocrinol (Copenh) 95:359-363, 1980
34. Madsbad S: Factors of importance for residual beta-cell function in type I diabetics: A review. Acta Med Scand 671:61-67, 1983
35. Madsbad S: Prevalence of residual beta-cell function and its metabolic consequences in type I (insulin-dependent) diabetes. Diabetologia 24:141-147, 1983
36. Karjalainen J, Salema P, Ilonen J, et al: A comparison of childhood and adult type I diabetes mellitus. N Engl J Med 320:881-886, 1989
37. Tarn AC, Smith CP, Spencer KM, et al: Type I (insulin-dependent) diabetes: A disease of slow clinical onset? BMJ 294:342-345, 1989
38. Levy-Marchal C, Papoz L, de Beaufort C, et al: Clinical and laboratory features of type 1 diabetes; diabetic children at time of diagnosis. Diabet Med 9:279-284, 1992